PRME
Prime Medicine, Inc. NASDAQ Listed Oct 20, 2022$3.12
Mkt Cap $562.4M
52w Low $1.11
34.4% of range
52w High $6.94
50d MA $3.72
200d MA $4.05
P/E (TTM)
-2.5x
EV/EBITDA
-2.9x
P/B
4.2x
Debt/Equity
1.0x
ROE
-166.4%
P/FCF
-3.1x
RSI (14)
—
ATR (14)
—
Beta
2.67
50d MA
$3.72
200d MA
$4.05
Avg Volume
2.5M
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
21 Erie Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 3.41 | +0.0% | -8.5% | +2.9% | — | — | — | — |
| Mar 3, 2026 | AMC | -0.25 | -0.22 | +12.0% | 4.23 | +1.2% | -2.6% | -4.6% | +2.0% | +2.5% | -1.5% | — |
| Nov 7, 2025 | AMC | -0.28 | -0.32 | -14.3% | 3.81 | +7.3% | -7.3% | +11.0% | -9.4% | -6.2% | +1.2% | — |
| Aug 7, 2025 | AMC | -0.36 | -0.41 | -13.9% | 3.68 | -0.3% | +3.0% | -7.4% | -1.4% | +10.1% | -4.5% | — |
| May 8, 2025 | AMC | -0.32 | -0.40 | -25.0% | 1.32 | +0.8% | -1.5% | +3.1% | -5.2% | -4.7% | +4.1% | — |
| Feb 28, 2025 | AMC | -0.37 | -0.31 | +16.2% | 2.52 | +2.8% | -11.1% | -1.3% | +4.5% | -0.4% | +4.3% | — |
| Nov 12, 2024 | AMC | -0.43 | -0.44 | -2.3% | 4.32 | -6.7% | -8.3% | -9.1% | -6.9% | -5.1% | -0.3% | — |
| Aug 8, 2024 | AMC | -0.40 | -0.46 | -15.0% | 4.39 | -1.4% | -4.3% | -1.7% | +3.9% | -4.2% | +6.8% | — |
| May 10, 2024 | AMC | -0.45 | -0.44 | +2.2% | 5.61 | +4.8% | +14.4% | +3.7% | +1.5% | +4.1% | +0.6% | — |
| Mar 1, 2024 | AMC | -0.48 | -0.56 | -16.7% | 8.74 | +1.9% | +0.3% | -8.0% | +4.3% | -3.3% | -0.7% | — |
| Nov 3, 2023 | AMC | -0.45 | -0.55 | -22.2% | 7.80 | +2.1% | -0.5% | +7.1% | -9.7% | -8.7% | -0.6% | — |
| Aug 7, 2023 | AMC | -0.42 | -0.47 | -11.9% | 12.55 | -2.5% | +1.3% | +0.1% | -4.6% | -3.6% | +4.6% | — |
| May 11, 2023 | AMC | -0.42 | -0.44 | -4.8% | 12.55 | -0.7% | +1.4% | +1.4% | -2.6% | +3.7% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11 | Citigroup | Maintains | Neutral → Neutral | — | $3.53 | $3.50 | -0.8% | +11.0% | -9.4% | -6.2% | +1.2% | +13.4% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $3.81 | $4.09 | +7.3% | -7.3% | +11.0% | -9.4% | -6.2% | +1.2% |
| Aug 12 | Citigroup | Maintains | Neutral → Neutral | — | $3.51 | $3.60 | +2.6% | -1.4% | +10.1% | -4.5% | -1.9% | -2.0% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $3.68 | $3.67 | -0.3% | +3.0% | -7.4% | -1.4% | +10.1% | -4.5% |
| May 27 | Citigroup | Downgrade | Buy → Neutral | — | $1.29 | $1.26 | -2.3% | -1.6% | +0.0% | -0.8% | -6.3% | +0.8% |
| May 20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.34 | $1.33 | -0.7% | -11.9% | -0.8% | +5.1% | +4.9% | -1.6% |
| May 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.34 | $1.33 | -0.7% | -11.9% | -0.8% | +5.1% | +4.9% | -1.6% |
| May 20 | JP Morgan | Downgrade | Overweight → Neutral | — | $1.34 | $1.33 | -0.7% | -11.9% | -0.8% | +5.1% | +4.9% | -1.6% |
| May 19 | Chardan Capital | Maintains | Buy → Buy | — | $1.59 | $1.39 | -12.6% | -15.7% | -11.9% | -0.8% | +5.1% | +4.9% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $2.00 | $2.06 | +3.0% | +0.5% | -3.0% | +4.1% | -3.9% | +0.0% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.77 | +0.6% | +13.6% | +0.5% | -3.0% | +4.1% | -3.9% |
| Mar 4 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $2.24 | $2.19 | -2.2% | -1.3% | +4.5% | -0.4% | +4.3% | -13.3% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $2.52 | $2.59 | +2.8% | -11.1% | -1.3% | +4.5% | -0.4% | +4.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.59 | +2.8% | -11.1% | -1.3% | +4.5% | -0.4% | +4.3% |
| Dec 3 | Guggenheim | Maintains | Buy → Buy | — | $3.45 | $3.46 | +0.3% | -9.3% | +1.9% | -6.9% | +10.1% | -1.5% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.18 | -0.5% | -4.0% | +4.5% | -3.1% | -0.2% | -4.7% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.39 | $4.33 | -1.4% | -4.3% | -1.7% | +3.9% | -4.2% | +6.8% |
| May 16 | Citigroup | Upgrade | Neutral → Buy | — | $6.76 | $6.90 | +2.1% | +4.1% | +0.6% | +6.4% | +6.6% | -7.2% |
| May 13 | JP Morgan | Maintains | Overweight → Overweight | — | $5.61 | $5.88 | +4.8% | +14.4% | +3.7% | +1.5% | +4.1% | +0.6% |
| Apr 23 | Wedbush | Maintains | Outperform → Outperform | — | $4.78 | $4.85 | +1.5% | +0.4% | -2.1% | -8.5% | +3.0% | +9.7% |
| Mar 8 | JP Morgan | Maintains | Overweight → Overweight | — | $8.14 | $8.40 | +3.2% | -0.7% | -0.6% | -4.0% | +2.9% | -13.1% |
| Mar 5 | Guggenheim | Maintains | Buy → Buy | — | $8.77 | $8.65 | -1.4% | -8.0% | +4.3% | -3.3% | -0.7% | -0.6% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $7.76 | $7.77 | +0.1% | +7.1% | -9.7% | -8.7% | -0.6% | -2.1% |
| Aug 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.69 | $11.66 | -0.3% | +4.6% | -2.3% | -2.7% | +1.8% | +0.8% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $16.74 | $16.63 | -0.7% | +0.7% | +0.5% | +1.7% | +1.3% | -2.8% |
No insider trades available.
8-K · 2.02
!! High
Prime Medicine, Inc. -- 8-K 2.02: Earnings Results
Prime Medicine reported financial results through an 8-K filing, with detailed earnings information available in the attached press release exhibit for investor review.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
PRME's new CFO hire signals operational maturity and potential financial restructuring; investors should monitor whether improved financial controls and capital allocation justify the added executive compensation costs.
Apr 16
8-K · 7.01
! Medium
Prime Medicine, Inc. -- 8-K 7.01: Regulation FD Disclosure
Prime Medicine updated its corporate presentation on March 3, 2026, providing investors with current company information through their investor relations website.
Mar 3
Data updated apr 26, 2026 8:46pm
· Source: massive.com